DMT Choice for Your MS Is Your Decision

Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report

Ocrevus Predicted to Be a Billion-dollar Blockbuster

Lupus Clinical Trials May Not Be Representative of Real-World Population, Report Suggests

Ocrevus Proves Mettle in Real-World PPMS – Adverse events from ongoing study in line with major trial results

Ustekinumab Makes Inroads in Crohn’s Disease – Docs opt for psoriasis drug when anti-TNF agents fail